PolyPid

An innovative biopharmaceutical company advancing long-acting, controlled release medicines that deliver therapy precisely at the site of care.

Health Tech & Life Sciences

Public on NASDAQ on Jun 2020

Public Petah Tikva, Israel Founded 2008

Last updated 2026-09-04

Went public on NASDAQ (PYPD), Jun 2020
Raised $60M Follow-on PO, Jun 2020
Raised $50M Series E led by existing shareholders, Sep 2019

Total raised

$176.5M

Last: B Round 2025-08

Stage

Public

Founded

2008

Headcount

Petah Tikva, Israel

Sector

Health Tech & Life Sciences

Website ↗LinkedIn ↗Registrar ID: 514105923 (PolyPid Ltd.)

About

PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the precise, controlled, and prolonged release of therapeutics, delivering drugs at optimal rates over extended durations. The company's lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. Additionally, PolyPid is developing OncoPLEX, which is in preclinical testing for treating solid tumors, including glioblastomas.

Funding history · 9 rounds · $176.5M total

11 events/rounds · $176.5M Total Funding: $92.8M in Private Equity, $158.9M in Public Equity

Nov 2025

Follow-on PO $15.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR

May 2023

Follow-on PO $8.7M EDGAR filing SEC-EDGAR filing SEC-EDGAR

Jun 2020

Follow-on PO $60.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR

Sep 2019

E Round $50.0M calcalistech.com ↗

★ existing shareholders★ Unspecified institutional shareholdersAurumUS investorsShavit CapitalCHealth VenturesFriendly Angels Club groupUS-based high-net-worth investorsExisting institutional shareholders

Nov 2018

D Round Extension $15.0M calcalistech.com ↗

★ Shareholders★ Shareholders and new investors

Feb 2016

D Round $22.0M prnewswire.com ↗

★ Shavit Capital★ Aurum VenturesChaim Hurvitzother existing shareholders

Dec 2012

C Round $2.4M globes.co.il ↗

★ Xenia Venture Capital

Jan 2012

B Round $2.0M globes.co.il ↗

2010

Seed $1.4M globes.co.il ↗

Headcount over time

83 employees (2026-09) · 1 point

Offices

Petah Tikva, Israel · HQ / main office

Q&A

What is PolyPid's primary focus?: PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which enables the precise, controlled, and prolonged release of therapeutics.
What is PolyPid's lead product candidate and its current development stage?: PolyPid's lead product candidate is D-PLEX100, which is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.
When did PolyPid become a public company?: PolyPid became public on NASDAQ in June 2020.
What was the amount raised in PolyPid's Initial Public Offering in June 2020?: PolyPid raised $60,000,000 in its Public Offering in June 2020.
What was the most recent public offering amount for PolyPid?: PolyPid's most recent public offering was in November 2025, raising $15,000,000.
What is the status of PolyPid's D-PLEX100 SHIELD II trial as of March 2025?: In March 2025, PolyPid announced the successful completion of enrollment in its Phase 3 SHIELD II trial of D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.
What was a significant development for PolyPid in June 2025 regarding its SHIELD II trial?: In June 2025, PolyPid announced positive topline results from its Phase 3 SHIELD II trial, where D-PLEX₁₀₀ demonstrated a significant reduction in surgical site infections and successfully met its primary and all key secondary endpoints.
What new delivery platform did PolyPid unveil in July 2025?: In July 2025, PolyPid unveiled a long-acting GLP-1 Receptor Agonists Delivery Platform, targeting the diabetes and weight loss market.
What regulatory milestone did PolyPid achieve in June 2026?: In June 2026, PolyPid completed its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀.

Team · 16

Noam Emanuel

Founder · Member of Scientific Advisory Board of Drug Delivery

Dikla Czaczkes Akselbrad

Chief Executive Officer

Dalit Fellous Hazan

Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs

Ori Warshavsky

Chief Operating Officer - US

Jean-Marc Hagai

Chief Commercial Officer

Jonny Missulawin

Chief Financial Officer

Tal Vilnai

General Counsel & Corporate Secretary

Maria Rubin

EVP, Operations

Rivi Lev-Ari

VP, Human Resources

Nurit Tweezer-Zaks

Chief Medical Officer

Brooke Story

Chairman of the Board of Directors

Yechezkel Barenholz